Ticker
$PLSE
1 catalyst touching PLSE in the last 60 days, newest first, each with the price move that followed.
- 72
PLSE reaches 164-patient enrollment target in nPulse cardiac ablation trial
Pulse Biosciences announced completion of enrollment in its NANOPULSE-AF pivotal IDE clinical study for the nPulse Cardiac Catheter System, enrolling 164 evaluable patients across 15 sites with first treatments in April 2026. Reaching enrollment target in a pivotal cardiac ablation trial is a material clinical milestone that removes execution risk and moves the company toward primary safety and effectiveness readout at 6 and 12 months, critical for potential FDA approval in a large symptomatic atrial fibrillation market.
PLSE ▲SEC 8-K · 7 Oct 2026, 13:06 UTC
Information only. AURA does not give buy or sell recommendations.